Pfizer vs. Teva: NURTEC ODT Patent Dispute Resolved in Delaware District Court

In a closely watched pharmaceutical patent infringement case, Pfizer, Inc. and Teva Pharmaceutical Industries, Ltd. reached a stipulated resolution on January 16, 2026, effectively ending a 603-day ANDA litigation battle over Pfizer’s blockbuster migraine drug, NURTEC ODT® (rimegepant sulfate). Filed in the Delaware District Court under Case No. 1:24-cv-00627, the dispute centered on U.S. Patent No. 11,083,724 B2 — a key intellectual property asset protecting one of the fastest-growing CGRP receptor antagonist products in the migraine treatment market.

The case’s resolution — achieved through voluntary dismissal without prejudice following Teva’s agreement to withdraw its pre-patent expiry FDA approval bid — carries significant implications for Hatch-Waxman litigation strategy, ANDA paragraph certification tactics, and pharmaceutical patent portfolio management. For patent attorneys, IP professionals, and R&D teams navigating the complex landscape of branded drug protection, this case offers instructive lessons in how originator pharmaceutical companies can leverage patent term certainty to resolve generic entry disputes efficiently.

Case Overview

The Parties

The Patent at Issue

The asserted patent, U.S. Patent No. 11,083,724 B2 (application number US16/884,196), covers formulation and/or composition claims associated with rimegepant sulfate — the active pharmaceutical ingredient in NURTEC ODT®. This orally dissolving tablet format is central to Pfizer’s commercial differentiation in the migraine treatment market.

The Accused Product

Teva’s Abbreviated New Drug Application (ANDA) product — a generic version of Pfizer’s NURTEC ODT® rimegepant sulfate tablet — was the accused product. The filing of the ANDA itself constituted the statutory act of infringement under 35 U.S.C. § 271(e)(2), the mechanism Congress established for Hatch-Waxman litigation.

Legal Representation

Pfizer was represented by Morris, Nichols, Arsht & Tunnell LLP. Teva was represented by Shaw Keller LLP.

Litigation Timeline & Procedural History

The complaint was filed on May 23, 2024, in the U.S. District Court for the District of Delaware — the preeminent venue for pharmaceutical Hatch-Waxman litigation. The case was presided over by Chief Judge Colm F. Connolly. The matter closed on January 16, 2026, after 603 days — a duration consistent with negotiated resolution during the standard 30-month stay period triggered by Paragraph IV ANDA certifications under the Hatch-Waxman Act.

The resolution — achieved through voluntary dismissal without prejudice following Teva’s agreement to withdraw its pre-patent expiry FDA approval bid — carries significant implications for Hatch-Waxman litigation strategy, ANDA paragraph certification tactics, and pharmaceutical patent portfolio management.

The Verdict & Legal Analysis

Outcome

The case concluded through a stipulated dismissal without prejudice, jointly filed by both parties and approved by the court. The core terms of the stipulation, as entered on January 16, 2026, were as follows:

• Teva agreed to withdraw its pre-expiry FDA approval request for its ANDA product, electing a Paragraph III certification with respect to the ‘724 Patent.
• All infringement claims and counterclaims related to the ‘724 Patent were dismissed without prejudice pursuant to Fed. R. Civ. P. 41(a)(1)(A)(ii) and 41(c).
• Pfizer agreed not to re-assert the ‘724 Patent against Teva’s ANDA or ANDA product, contingent on Teva maintaining its Paragraph III certification.
• Each party bears its own fees and costs, with no damages awarded.
• The court retained jurisdiction to enforce the stipulation’s terms.

No monetary damages were awarded. No injunctive relief was formally issued, as the stipulation itself achieved the functional equivalent — Teva’s removal from the pre-expiry approval queue.

Verdict Cause Analysis

This case was an infringement action under the Hatch-Waxman Act, where the mere filing of an ANDA with a Paragraph IV certification constitutes an act of infringement under 35 U.S.C. § 271(e)(2). The fact that Teva converted to a Paragraph III certification — rather than prevailing on invalidity or non-infringement grounds — suggests Pfizer’s patent position was sufficiently strong to make continued litigation commercially unattractive for Teva.

Legal Significance

While this case produced no formal claim construction ruling or validity determination, its outcome reinforces several important Hatch-Waxman dynamics:

• Paragraph III conversions as a resolution mechanism: Innovators can effectively “win” ANDA litigation without a merits ruling when generic challengers withdraw their pre-expiry approval bids.
• The 30-month stay’s strategic value: The Hatch-Waxman framework’s automatic stay provides innovators time to litigate or negotiate, here resulting in a resolution that preserves patent term protection.
• Dismissal without prejudice with non-assertion agreements: The mutual structure — dismissal without prejudice paired with a conditional non-assertion covenant — is a recognized and balanced resolution mechanism preserving optionality for both parties.

Industry & Competitive Implications

The Pfizer v. Teva rimegepant outcome reflects broader trends in branded pharmaceutical patent enforcement. The CGRP antagonist migraine market is a high-value therapeutic space where patent term protection directly translates to billions in revenue.

Teva’s decision to stand down also signals the continued potency of formulation patents as secondary patent layers that outlast primary compound protections. For generic manufacturers, this case illustrates the risk calculus involved in mounting multi-patent ANDA challenges: even one defensible patent in an innovator’s portfolio can delay market entry or increase litigation costs beyond acceptable thresholds.

From a market perspective, Pfizer retains NURTEC ODT® exclusivity for the ‘724 Patent’s remaining term, maintaining its competitive position against both branded CGRP competitors and potential generic entrants.